Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$17.99
At close: May 20 EDT
$17.99
0.000.00%
Pre-Market: 4:00 PM EDT
Comments
Loading...
NeuroPace Analyst Ratings and Price Targets | NASDAQ:NPCE | Benzinga
NeuroPace Inc has a consensus price target of $15.78 based on the ratings of 9 analysts. The high is $22 issued by Leerink Partners on January 30, 2024. The low is $8 issued by Morgan Stanley on July 15, 2024. The 3 most-recent analyst ratings were released by JP Morgan, Cantor Fitzgerald, and Cantor Fitzgerald on May 14, 2025, May 14, 2025, and March 5, 2025, respectively. With an average price target of $17.67 between JP Morgan, Cantor Fitzgerald, and Cantor Fitzgerald, there's an implied -1.80% downside for NeuroPace Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
Cantor Fitzgerald
Wells Fargo
UBS
Wells Fargo
1calculated from analyst ratings
Analyst Ratings for NeuroPace
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/14/2025 | Buy Now | -11.06% | JP Morgan | Robbie Marcus67% | $14 → $16 | Maintains | Overweight | Get Alert |
| 05/14/2025 | Buy Now | -5.5% | Cantor Fitzgerald | Ross Osborn46% | $17 → $17 | Reiterates | Overweight → Overweight | Get Alert |
| 03/05/2025 | Buy Now | 11.17% | Cantor Fitzgerald | Ross Osborn46% | $19 → $20 | Maintains | Overweight | Get Alert |
| 01/30/2025 | Buy Now | -5.5% | Wells Fargo | Larry Biegelsen67% | $13 → $17 | Maintains | Overweight | Get Alert |
| 01/21/2025 | Buy Now | -5.5% | UBS | Priya Sachdeva43% | → $17 | Initiates | → Buy | Get Alert |
| 12/17/2024 | Buy Now | -22.18% | JP Morgan | Robbie Marcus67% | $9 → $14 | Maintains | Overweight | Get Alert |
| 11/13/2024 | Buy Now | -27.74% | Wells Fargo | Vik Chopra49% | $15 → $13 | Maintains | Overweight | Get Alert |
| 08/14/2024 | Buy Now | 0.06% | Cantor Fitzgerald | Ross Osborn46% | $18 → $18 | Reiterates | Overweight → Overweight | Get Alert |
| 08/14/2024 | Buy Now | -16.62% | Wells Fargo | Vik Chopra49% | $20 → $15 | Maintains | Overweight | Get Alert |
| 07/15/2024 | Buy Now | -55.53% | Morgan Stanley | Drew Ranieri47% | $9.5 → $8 | Maintains | Equal-Weight | Get Alert |
| 05/09/2024 | Buy Now | 0.06% | Cantor Fitzgerald | Ross Osborn46% | $18 → $18 | Reiterates | Overweight → Overweight | Get Alert |
| 03/14/2024 | Buy Now | 11.17% | Wells Fargo | Lawrence Biegelsen48% | $16 → $20 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 03/12/2024 | Buy Now | -5.5% | JP Morgan | Robbie Marcus67% | $9 → $17 | Maintains | Overweight | Get Alert |
| 03/06/2024 | Buy Now | 0.06% | Cantor Fitzgerald | Ross Osborn46% | $16 → $18 | Maintains | Overweight | Get Alert |
| 03/06/2024 | Buy Now | -27.74% | Morgan Stanley | Drew Ranieri47% | $9 → $13 | Maintains | Equal-Weight | Get Alert |
| 02/22/2024 | Buy Now | -11.06% | Wells Fargo | Lawrence Biegelsen48% | $9 → $16 | Maintains | Equal-Weight | Get Alert |
| 01/30/2024 | Buy Now | 22.29% | Leerink Partners | Mike Kratky65% | → $22 | Initiates | → Outperform | Get Alert |
| 12/27/2023 | Buy Now | -33.3% | Lake Street | Frank Takkinen35% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 12/04/2023 | Buy Now | -49.97% | Morgan Stanley | Drew Ranieri47% | $8 → $9 | Maintains | Equal-Weight | Get Alert |
| 11/14/2023 | Buy Now | -55.53% | Morgan Stanley | Drew Ranieri47% | $6 → $8 | Maintains | Equal-Weight | Get Alert |
| 11/10/2023 | Buy Now | -38.85% | Cantor Fitzgerald | Ross Osborn46% | → $11 | Initiates | → Overweight | Get Alert |
| 11/07/2023 | Buy Now | -49.97% | JP Morgan | Robbie Marcus67% | $6 → $9 | Maintains | Overweight | Get Alert |
| 10/04/2023 | Buy Now | -49.97% | Wells Fargo | Lawrence Biegelsen48% | $6 → $9 | Maintains | Equal-Weight | Get Alert |
| 08/24/2023 | Buy Now | -66.65% | Morgan Stanley | Drew Ranieri47% | $5 → $6 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 05/05/2023 | Buy Now | -72.21% | Morgan Stanley | Drew Ranieri47% | $4.5 → $5 | Maintains | Underweight | Get Alert |
| 03/03/2023 | Buy Now | -74.99% | Morgan Stanley | Drew Ranieri47% | $2.5 → $4.5 | Maintains | Underweight | Get Alert |
| 02/22/2023 | Buy Now | -44.41% | Lake Street | Frank Takkinen35% | → $10 | Initiates | → Buy | Get Alert |
| 01/06/2023 | Buy Now | -86.1% | Morgan Stanley | Drew Ranieri47% | $3.5 → $2.5 | Maintains | Underweight | Get Alert |
| 10/11/2022 | Buy Now | -80.54% | Morgan Stanley | Drew Ranieri47% | $5.5 → $3.5 | Maintains | Underweight | Get Alert |
| 07/15/2022 | Buy Now | -69.43% | Morgan Stanley | Drew Ranieri47% | $6 → $5.5 | Maintains | Underweight | Get Alert |
FAQ
What is the target price for NeuroPace (NPCE) stock?
The latest price target for NeuroPace (NASDAQ:NPCE) was reported by JP Morgan on May 14, 2025. The analyst firm set a price target for $16.00 expecting NPCE to fall to within 12 months (a possible -11.06% downside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for NeuroPace (NPCE)?
The latest analyst rating for NeuroPace (NASDAQ:NPCE) was provided by JP Morgan, and NeuroPace maintained their overweight rating.
When was the last upgrade for NeuroPace (NPCE)?
The last upgrade for NeuroPace Inc happened on March 14, 2024 when Wells Fargo raised their price target to $20. Wells Fargo previously had an equal-weight for NeuroPace Inc.
When was the last downgrade for NeuroPace (NPCE)?
There is no last downgrade for NeuroPace.
When is the next analyst rating going to be posted or updated for NeuroPace (NPCE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NeuroPace, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NeuroPace was filed on May 14, 2025 so you should expect the next rating to be made available sometime around May 14, 2026.
Is the Analyst Rating NeuroPace (NPCE) correct?
While ratings are subjective and will change, the latest NeuroPace (NPCE) rating was a maintained with a price target of $14.00 to $16.00. The current price NeuroPace (NPCE) is trading at is $17.99, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
